Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-1 Vaccine + IL-2 in Stage IV Renal Cell Carcinoma
NCT00031564Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2000
- Primary completion
- Jun 2005
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of B7-1 gene-modified autologous tumor cell vaccine in renal cell carcinoma (RCC), sponsored by Moffitt Cancer Center. Primary endpoint: Percentage of Patients Who Have a Reduction in the Size of Their Measurable Metastatic Tumors at 4 years. Started May 2000; status: completed.
02
Drugs
B7-1 gene-modified autologous tumor cell vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00031564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031564.